Background: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in EGFR mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.